Ratings Omda

Equities

CSAM

NO0010894512

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-02 am EDT			5-day change	1st Jan Change
36 ^NOK	0.00%		+6.19%	-2.70%

Apr. 25	Omda AS Announces Board Appointments	CI
Mar. 01	Tranche Update on Omda AS (OB:OMDA)'s Equity Buyback Plan announced on January 30, 2023.	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
One of the major weak points of the company is its financial situation.
With an expected P/E ratio at 80.2 and 32.14 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
OMDA	-2.70%	66.43M		-
VEEVA SYSTEMS INC.	+4.63%	32.15B		C
PRO MEDICUS LIMITED	+16.98%	7.41B		C-
SECTRA AB	+20.94%	3.85B		B-
EVOLENT HEALTH, INC.	-17.01%	3.13B		C-
OMNICELL, INC.	-22.16%	1.25B		B
LUNIT INC.	-31.01%	1.17B		-
SIMULATIONS PLUS, INC.	+4.40%	926M		C
B-SOFT CO.,LTD.	-34.81%	911M		-
VERADIGM INC.	-25.64%	842M	-	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes